SAM
SRPT icon

Symphony Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

Symphony Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-3,602
Closed -$266K – 288
2018
Q1 		$266K Buy
+3,602
New +$240K 0.03% 314

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Symphony Asset Management's SRPT Position: Q2 2018 in Review

Symphony Asset Management sold out of Sarepta Therapeutics (SRPT) in Q2 2018, closing a stake of 3,602 shares — an estimated $266K sold.

Symphony Asset Management first reported a position in SRPT in Q1 2018 and held it in 1 quarter. The position peaked at $266K in Q1 2018. 317 funds tracked by Wall St. Rank hold SRPT as of Q2 2018.

  • Symphony Asset Management reported no remaining Sarepta Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Symphony Asset Management sold 3,602 Sarepta Therapeutics shares in Q2 2018, an estimated $266K.
  • Symphony Asset Management first reported a position in Sarepta Therapeutics in Q1 2018 and held it in 1 quarter.
  • Symphony Asset Management's Sarepta Therapeutics position peaked at $266K in Q1 2018.
  • 317 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2018.

Based on Symphony Asset Management's 13F filing for Q2 2018, filed 14 Aug 2018.